PARP1 and breast carcinoma: Not only PARP inhibitors have gained much attention in treating breast cancer, but also other enzymes including Polβ, APE1, and DNA ligases are potential pharmacological targets by altering the amounts of BER proteins to eliminate cancer cells [24].